Differential immunotropic therapy of patients with acne

Abstract

Acne (Acne vulgaris) is one of the most common skin diseases (registered in 80-90% of teenagers and young people of working age) with the localization of acne on exposed skin, has a chronic course that causes psycho-emotional changes in patients and reduces their quality of life. Objective. To improve the treatment of patients with acne depending on the clinical manifestations of dermatosis and the state of their systemic immunity through the differentiated use of immunotropic drugs. Material and methods. A comprehensive immunological examination and treatment of 146 patients with acne aged 19 to 25 years, of which 77 (52.7%) were female and 69 (47.3%) were male. The control group consisted of 35 healthy individuals (donors) of similar age and sex. Results. All 146 examined patients with acne were diagnosed with an inflammatory form of acne, including: in 37 (25.3%) patients-mild clinical course, in 83 (56.8%)-moderate severity and in 26 (17.9%)severe clinical course of acne. The immunological study revealed significant changes in immune parameters in patients with severe and moderate clinical course of acne, while a slight change in the immunity was found in the patients with mild stage of acne. According to these changes in the immunological parameters of patients with acne, an immunotropic drug glucosaminylmuramyl dipeptide (lycopid) was prescribed differently-2 mg twice a day for 10 days (for the patients with moderate acne) and 10 mg once a day for 10 days (for the patients with severe clinical picture). This kind of treatment led to a positive dynamics of immunological parameters of the blood in such patients. Conclusion. Differentiated immunotropic therapy as a component of complex treatment of patients with acne with the prescribtion of the immunotropic drug glucosaminylmuramyl dipeptide (lycopid) allows us to improve the results of treatment, which is confirmed by the significant positive dynamics of clinical and laboratory parameters.